GlassScriptPhysician profile
Sarah B Carroll
NPI 1457642605
$1,767.92
in general payments reported to CMS, 2019-2025
19 companies · $689 in 2025
The $689 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $25.88 · 2021: $245 · 2022: $165 · 2023: $202 · 2024: $203 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594 · Long Term Medical Supply Or Device Loan: $399 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.32 |
| Long Term Medical Supply Or Device Loan | $398.80 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $415.85 | 2025 | |
| Janssen Biotech, INC. | $413.55 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Seagen INC. | $198.95 | 2021-2023 | |
| Celgene Corporation | $188.83 | 2021-2025 | Reblozyl, Opdualag |
| Pfizer INC. | $101.30 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $99.32 | 2019-2025 | Opdivo, Krazati |
| Abbvie INC. | $64.72 | 2024-2025 | |
| Sirtex Medical INC | $43.36 | 2022-2024 | Sir-Spheres Microspheres |
| Astrazeneca Pharmaceuticals LP | $32.08 | 2022-2024 | Enhertu |
| Gilead Sciences, INC. | $30.27 | 2021-2025 | Trodelvy |
| Fennec Pharmaceuticals, INC. | $24.70 | 2025 | Fyarro |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.32 | 2025 | Ultomiris |
| Blue Earth Diagnostics | $19.45 | 2024 | |
| Boston Scientific Corporation | $19.39 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18.67 | 2019 | |
| Amgen INC. | $18.13 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.67 | 2022 | |
| Merck Sharp & Dohme LLC | $16.43 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.